| Identification of a chromosome 18q gene that is altered in colorectal cancers ER Fearon, KR Cho, JM Nigro, SE Kern, JW Simons, JM Ruppert, ... Science 247 (4938), 49-56, 1990 | 2309 | 1990 |
| p53-mediated activation of miRNA34 candidate tumor-suppressor genes GT Bommer, I Gerin, Y Feng, AJ Kaczorowski, R Kuick, RE Love, Y Zhai, ... Current biology 17 (15), 1298-1307, 2007 | 1428 | 2007 |
| Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy D Peng, I Kryczek, N Nagarsheth, L Zhao, S Wei, W Wang, Y Sun, E Zhao, ... Nature 527 (7577), 249-253, 2015 | 1063 | 2015 |
| Scrambled exons JM Nigro, KR Cho, ER Fearon, SE Kern, JM Ruppert, JD Oliner, ... Cell 64 (3), 607-613, 1991 | 991 | 1991 |
| Mutations in PTEN Are Frequent in Endometrial Carcinoma But Rare in Other Common Gynecological Malignancies H Tashiro, MS Blazes, R Wu, KR Cho, S Bose, SI Wang, J Li, R Parsons, ... Cancer research 57 (18), 3935-3940, 1997 | 988 | 1997 |
| DPC4 Gene in Various Tumor Types M Schutte, RH Hruban, L Hedrick, KR Cho, GM Nadasdy, CL Weinstein, ... Cancer research 56 (11), 2527-2530, 1996 | 987 | 1996 |
| Ovarian cancer KR Cho, IM Shih Annual review of pathology: mechanisms of disease 4, 287-313, 2009 | 951 | 2009 |
| Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology WJ Koh, NR Abu-Rustum, S Bean, K Bradley, SM Campos, KR Cho, ... Journal of the National Comprehensive Cancer Network 17 (1), 64-84, 2019 | 858 | 2019 |
| Frequency of homozygous deletion at p16/CDKN2 in primary human tumours P Cairns, TJ Polascik, Y Eby, K Tokino, J Califano, A Merlo, L Mao, ... Nature genetics 11 (2), 210-212, 1995 | 827 | 1995 |
| Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer CD Hough, CA Sherman-Baust, ES Pizer, FJ Montz, DD Im, ... Cancer Research 60 (22), 6281-6287, 2000 | 700 | 2000 |
| Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. TD Kessis, RJ Slebos, WG Nelson, MB Kastan, BS Plunkett, SM Han, ... Proceedings of the National Academy of Sciences 90 (9), 3988-3992, 1993 | 666 | 1993 |
| Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology WJ Koh, NR Abu-Rustum, S Bean, K Bradley, SM Campos, KR Cho, ... Journal of the National Comprehensive Cancer Network 16 (2), 170-199, 2018 | 632 | 2018 |
| A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability LL Myeroff, R Parsons, SJ Kim, L Hedrick, KR Cho, K Orth, M Mathis, ... Cancer research 55 (23), 5545-5547, 1995 | 594 | 1995 |
| Genetic alterations in the adenoma–carcinoma sequence KR Cho, B Vogelstein Cancer 70 (S4), 1727-1731, 1992 | 570 | 1992 |
| Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells CA Sherman-Baust, AT Weeraratna, LBA Rangel, ES Pizer, KR Cho, ... Cancer cell 3 (4), 377-386, 2003 | 560 | 2003 |
| p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. H Tashiro, C Isacson, R Levine, RJ Kurman, KR Cho, L Hedrick The American journal of pathology 150 (1), 177, 1997 | 506 | 1997 |
| Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas DR Schwartz, SLR Kardia, KA Shedden, R Kuick, G Michailidis, ... Cancer research 62 (16), 4722-4729, 2002 | 488 | 2002 |
| p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. RJ Slebos, MH Lee, BS Plunkett, TD Kessis, BO Williams, T Jacks, ... Proceedings of the National Academy of Sciences 91 (12), 5320-5324, 1994 | 484 | 1994 |
| Activation of AXIN2 expression by β-catenin-T cell factor: a feedback repressor pathway regulating Wnt signaling JY Leung, FT Kolligs, R Wu, Y Zhai, R Kuick, S Hanash, KR Cho, ... Journal of Biological Chemistry 277 (24), 21657-21665, 2002 | 452 | 2002 |
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. TC Wu, FG Guarnieri, KF Staveley-O'Carroll, RP Viscidi, HI Levitsky, ... Proceedings of the National Academy of Sciences 92 (25), 11671-11675, 1995 | 441 | 1995 |
